Millennium’s oral proteasome inhibitor (MLN9708) puts-up good study numbers at ASH

To contact us Click HERE

Much more from me about ASH later today.  Check that.  I have enough news and data to analyze and share for the next two weeks!  In the meantime it sounds like some medical reporters are impressed with Millennium’s MLN9708 study results here at ASH.  Take a look:

New Oral Drug in Multiple Myeloma May Be ‘Game Changer’

Zosia Chustecka – Medscape.com – December 9th, 2012

ATLANTA, Georgia — An investigational drug for multiple myeloma, the first oral proteasome inhibitor, has shown promising results in an early phase1/2 clinical trial and has progressed straight into phase 3 clinical trials. If all goes well, it is predicted to reach the market in 2014.

Currently known only as MLN9708 (Millennium), this new drug is taken orally once weekly and will offer an alternative to bortezomib ( Velcade, Millennium), the first proteosome inhibitor developed for multiple myeloma, which is now commonly used in the treatment of this disease.

The new drug offers the convenience of oral administration, inasmuch as bortezomib is parenterally administered. Initially it was available only for intravenous infusion, but now a subcutaneous formulation is also available.

In addition, the new drug appears to be associated with a reduced incidence of peripheral neuropathy as an adverse effect when compared with bortezomib…

This is only an excerpt.  CLICK HERE to access the Zosia’s article.  The thing that impresses me most is that MLN9708 looks like it will work in a significant number of patients who have become refractory to Velcade.

Feel good and keep smiling!  Pat